OP01 Ultra-Fast Wholebody Oncologic FDG PET/CT: A new capability enabled by digital photon counting PET/CT technology
K. Binzel1, A. Adelaja1, C. L. Wright1, D. Scharre2, J. Zhang1, M. V. Knopp1
1Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA; 2Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA
Correspondence: K. Binzel
OP02 The FALCON trial: Impact of 18F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent prostate cancer
E. J. Teoh1, D. Bottomley2, A. Scarsbrook2, H. Payne3, A. Afaq3, J. Bomanji3, N. van As4, S. Chua4, P. Hoskin5, A. Chambers5, G. J. Cook6, V. S. Warbey6, A. Chau7, P. Ward7, M. P. Miller7, D.J. Stevens7, L. Wilson7, F. V. Gleeson1
1Departments of Radiology and Nuclear Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; 2The Leeds Teaching Hospitals NHS Trust, Leeds, UK; 3University College London, London, UK; 4The Royal Marsden NHS Foundation Trust, London, UK; 5Mount Vernon Cancer Centre, London, UK; 6King's College London, London, UK; 7Blue Earth Diagnostics, Oxford, UK
Correspondence: E. J. Teoh
Patients | N = 85 |
---|---|
Detection rate: | n (%) |
Patient | 44/85 (51.8) |
Prostate/bed | 34/85 (40.0) |
Extraprostatic | 19/85 (22.4) |
Pelvic lymph nodes | 12/85 (14.1) |
Bone | 9/85 (10.6) |
CIM: n (%) | 52/85 (61.2) |
Prior RP | 24/52 (46.2) |
Positive 18F-fluciclovine scan | 41/52 (78.8) |
Major CIM: n (%) | 31/52 (59.6) |
Salvage therapy to watchful waiting | 13/52 (25.0) |
Salvage therapy to systemic therapy | 18/52 (34.6) |
Other CIM: n (%) | 21/52 (40.4) |
Modified RT field | 21/52 (40.4) |
OP03 Bi-213-anti-EGFR-MAb therapy of recurrent bladder cancer
K. Scheidhauer1, C. Seidl1, M. Autenrieth2, F. Bruchertseifer3, C. Apostolidis3, F. Kurtz2, T. Horn2, C. Pfob1, M. Schwaiger1, J. Gschwend2, C. D’Alessandria1, A. Morgenstern3
1TU München, Klinikum rechts der Isar, Nuklearmedizin, München, Germany; 2TU München, Klinikum rechts der Isar, Urologie, München, Germany; 3JRC, Institute for Transuranium, Karlsruhe, Germany
Correspondence: K. Scheidhauer
OP04 Early PET imaging of 68Ga-PSMA-11 PET/CT increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence
C. Uprimny, A. Kroiss, C. Decristoforo, E. von Guggenberg, B. Nilica, W. Horninger, I. Virgolini
Department of Nuclear Medicine, Medical University Innsbruck, Austria; Anichstrasse 32, 6020 Innsbruck, Austria
Correspondence: C. Uprimny
OP05 Gender Specific Analysis of 11C-Methionine PET Examination in Patients with Newly Diagnosed Gliomas
S. Rasul1, N. Poetsch1, A. Woehrer2M. Preusser3, M. Mitterhauser1, W. Wadsak14,, G. Widhalm5, M. Mischkulnig5, M. Hacker1, T. Traub-Weidinger1
1Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria; 2Clinical Institute of Neurology, Medical University of Vienna, Vienna, Austria; 3Clinical University of Internal Medicine I, Medical University of Vienna, Vienna, Austria; 4CBmed GmbH, Center for Biomarker Research in Medicine, Graz, Austria; 5Clinical University of Neuro-surgery, Medical University of Vienna, Vienna, Austria
Correspondence: S. Rasul
OP06 Assessing Post-Radioembolization Lung Shunt Fraction of Yttrium-90 Microspheres: A Clinical Feasibility Study Using Digital Photon Counting PET/CT
C. L. Wright1, K. Binzel1, E. J. Wuthrick2, E. D. Miller2, P. Maniawski3, J. Zhang1, M. V. Knopp1
1Wright Center of Innovation, The Ohio State University, Columbus, OH, USA; 2Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA; 3Clinical Science, Philips Healthcare, Cleveland, OH, USA
Correspondence: C. L. Wright
OP07 Patient radiation exposure after parathyroid imaging in nuclear medicine
Sebastijan Rep1, Marko Hocevar2, Janja Vaupotic3, Urban Zdesar4, Katja Zaletel1, Luka Lezaic1
1Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia; 2Department of Oncological Surgery, Oncology Institute Ljubljana, Ljubljana, Slovenia; 3Jozef Stefan Institute Ljubljana, Ljubljana, Slovenia; 4Institute of Occupational Safety Ljubljana, Ljubljana, Slovenia
Correspondence: Sebastijan Rep
OP08 Sex differences in blood pharmacokinetics and metabolism of (S)-[18F]THK5117 and [18F]THK5351 in rats
S. Mairinger1, Thomas Filip1, M. Sauberer1, S. Flunkert2, T. Wanek1, J. Stanek1,3, N. Okamura4, O. Langer1,3, C. Kuntner1
1Biomedical Systems, Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria; 2Neuropharmacology, QPS Austria GmbH, Grambach, Austria; 3Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; 4Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan
Correspondence: S. Mairinger
OP09 High diagnostic value of a new renal tubular imaging agent “L – Ethylenedicysteine” in children dynamic scintigraphy
M. C. Fornito1, R. Balzano1, V. Di Martino1, S. Cacciaguerra2, G. Russo3
1Nuclear Medicine Department PET/TC center Arnas Garibaldi Catania, Catania, Italy; 2Pediatric Surgery Department Arnas Garibaldi Catania, Catania, Italy; 3H. Pharmacy Department Arnas Garibaldi Catania, Catania, Italy
Correspondence: M. C. Fornito
OP10 Peptides labelling with 64Cu and 68Ga on heterogeneous phase using a microfludic system
D. Seifert1, M. Kleinova1, A. Cepa1, J. Ralis1, P. Hanc1, O. Lebeda1, M. Mosa2
1Nuclear Physics Institute of the CAS, Rez, Czech Republic; 2Charles university Faculty of Science Prague, Prague, Czech Republic
Correspondence: D. Seifert
OP11 PET20.0: Design of a monolithic Total Body PET with 2.00 mm spatial resolution and 20 x higher sensitivity
S. Vandenberghe1, E. Mikhaylova2, D. Borys3, V. Viswanath4, M. Stockhoff1, N. Efthimiou5, P. Caribe1, R. Van Holen1, J. S. Karp4
1MEDISIP research group, Ghent University, Ghent, Belgium; 2UC Davis, Davis, CA, USA; 3Silesian University of Technology Gliwice, Gliwice, Poland; 4PET instrumentation group, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 5University of Hull, UK
Correspondence: S. Vandenberghe
OP12 Clinical validation of EARL-compliant reconstruction of digital photon counting PET/CT: An intra-individual clinical comparison study to conventional photomultiplier tube-based PET/CT
K. Binzel1, J. Zhang1, C. L. Wright1, P. Maniawski2, M. V. Knopp1
1Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA; 2Philips Healthcare, Cleveland, Ohio, USA
Correspondence: K. Binzel
PP01 Relationship of dual time point myocardial SPECT-CT with peak creatine kinase and cardiac troponin I levels
P. M Haller1,2, C. Farhan3, E. Piackova1,2, B. Jäger1,2,5, P. Knoll3, A. Kiss4, B. K. Podesser2,4, J. Wojta2,5, K. Huber1,2,6, S. Mirzaei3
13rd Department of Medicine, Cardiology and Intensive Care Medicine, Chest Pain Unit, Wilhelminenhospital Vienna, Vienna, Austria; 2Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria; 3Department of Nuclear Medicine with PET-Center, Wilhelminenhospital, Vienna, Austria; 4Department of Biomedical Research, Medical University of Vienna, Vienna, Austria; 5Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria; 6Sigmund Freud University, Medical Faculty, Vienna, Austria
Correspondence: C. Farhan
PP02 Visualization of Abcg2 transport activity in the liver with [11C]erlotinib and positron emission tomography
A. Traxl1, K. Komposch2, Elisabeth Glitzner2, T. Wanek1, S. Mairinger1, M. Sibilia2, O. Langer1,3,4
1Center for Health & Bioresources, Biomedical Systems, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria; 2Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; 3Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; 4Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria
Correspondence: A. Traxl
PP03 Role of 18F-FDG PET in differentiation of Portal Malignant Thrombus from Bland Thrombus in patient with Hepatocellular carcinoma (HCC): a case report
M. C.Fornito1, M. Russello2, G. Russo3, R. Balzano1
1Nuclear Medicine Department PET/TC Center ARNAS Garibaldi, Catania, Italy; 2Liver Unit ARNAS Garibaldi, Catania, Italy; 3H.Pharmacy Department ARNAS Garibaldi, Catania, Italy
Correspondence: M. C. Fornito
PP04 Lenvatinib-therapy for patients with radioiodine-refractory differentiated thyroid cancer – our experiences with Lenvima® at the Department of Nuclear Medicine and Endocrinology in Klagenfurt, Austria
S. Sorko, H. J. Gallowitsch, S. Kohlfuerst, S. Matschnig, M. Rieser, M. Sorschag, P. Lind
Department of Nuclear Medicine and Endocrinology, PET/CT Center, Klinikum Klagenfurt, Klagenfurt, Austria
Correspondence: S. Sorko
PP05 The influence of attenuation correction and acquisition time on the SPECT image quality
L. Ležaič1 S. Rep1, J. Žibert2, N. Frelih1, S. Šuštar1
1Departments of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia; 2Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia
Correspondence: S. Šuštar
PP06 Optimization of high definition digital PET/CT reconstruction for neurologic imaging
K. Binzel1, A. Adelaja1, C. L. Wright1, D. Scharre2, J. Zhang1, M. V. Knopp1
1Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA; 2Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA
Correspondence: K. Binzel
PP07 Injection of botulinum toxin for preventing salivary gland toxicity after PSMA-Radio-Ligand-Therapy - an empiric proof of concept for the future
R. P. Baum1#, T. Langbein1#, A. Singh1, M. Shahinfar1, C. Schuchardt1, G. F. Volk2, H. R. Kulkarni1
1Theranostics Center for Molecular Radiotherapy and Molecular ImagZentralklinik Bad Berka, Bad Berka, Germany; 2Department of Otorhinolaryngology, Jena University Hospital, Jena, Germany
Correspondence: R. P. Baum; T. Langbein
PP08 Assessment of renal scars and differential renal function (DRF) in children with ureteral reflux: Tc 99m L-ethylenedicysteine dynamic scan vs Tc 99m DMSA static scan
M. C. Fornito1, S. Cacciaguerra2, R. Balzano1, G. V. Di Martino1, G. Russo3
1Nuclear Medicine Department Arnas Garibaldi, Catania, Italy; 2Pediatric Surgery Arnas Garibaldi, Catania, Italy; 3Pharmacy H. Department Arnas Garibaldi, Catania, Italy
Correspondence: M. C. Fornito
PP09 A New Program for the Optimisation of Mo99-Tc99m Generator Selection
W. H. Thomson
Physics and Nuclear Medicine, City Hospital, Birmingham UK
-
Manufacturers’ generators can occupy separate worksheets.
-
These individual worksheets are now separately selectable (included or excluded)
-
Calculation of each generator Tc99m activity is automatic (this significantly aids data entry)
-
Generators are pre-populated for major manufacturers so only the local costs are entered.
-
7day or 14day generator use is user selectable.
-
Results are sorted in order of increasing cost, so usually only the first batch of results need to be reviewed.
PP10 Interdisciplinary preoperative management of thyroid patients and thyroid cancer incidence
M. Kudlacek1, M. Karik2, C. Farhan1, H. Rieger3, W. Pokieser3, K. Glaser2, S. Mirzaei1
1Institute of Nuclear Medicine with PET-Center, Wilhelminenspital, Vienna, Austria; 2Department of Viceral and General Surgery, Wilhelminenspital, Vienna, Austria; 3Institute of Pathology and Microbiology, Wilhelminenspital, Vienna, Austria
Correspondence: M. Kudlacek
Year | (f) | (m) | Total |
---|---|---|---|
2012 | 17 | 6 | 14 |
2013 | 20 | 17 | 19 |
2014 | 18 | 31 | 21 |
2015 | 22 | 9 | 19 |
2016 | 31 | 27 | 30 |